Vet Clin Path Journal Fri, 03 Dec 2021 04:54:19 +0000 en-US hourly 1 Vet Clin Path Journal 32 32 SKUAST-Jammu is organizing a workshop on “Veterinary Practices and Updates” Fri, 03 Dec 2021 03:17:08 +0000

Faculty of Veterinary and Livestock Sciences, RS Pura today hosted a one-day workshop on “Veterinary Practices and Updates” for field veterinarians and postgraduate students. The event, organized under the aegis of “Azadi ka Amrit Mahotsav” aimed to update participants’ knowledge on various recent dimensions of veterinary practices. Prof. JP Sharma, Vice-Chancellor, SKUAST-Jammu opened the workshop as guest of honor in the presence of Dr Doifode Sagar Dattatray, Director, Department of Breeding, Jammu and Shri Krishan Lal, JKAS, Director, Sheep Breeding Department, Jammu, who were Guest of Honor during the function. Sharma, in her speech, said that field veterinarians and other responsible stakeholders related to agriculture and allied sectors should work to meet the needs and aspirations of the farming community and that our research and development work should also focus on the same. He advocated for the organization of workshops and similar brainstorming sessions of 2-3 days on different topics related to breeding. He also said that the strength of the Jammu region must be capitalized to uplift the socio-economic conditions of the people. He informed the assembly that Jammu District has been selected for dairy development under a one-product district program. He further stressed that it was high time to focus more on processing, adding value and marketing, rather than just producing the product.

Labeling, packaging and certification of agricultural and livestock products are the other areas where a lot of effort is needed. The Director, Department of Animal Husbandry, Jammu, said in his speech that animal husbandry is the sector that can fulfill the Prime Minister’s ambitious mission of doubling the income of farmers and the Department of Animal Husbandry, Jammu has the ability to do so. He spoke about current and future trends in veterinary practices as well as the dynamic socio-economic conditions of society. The livestock manager also emphasizes the different livestock programs managed by the department and how these programs can improve farmers’ incomes. in the treatment of diseases of livestock as well as conventional modern allopathic practices to reduce the problem of antimicrobial resistance, which will be good for the health and welfare of humans and animals. SKUAST-Jammu welcomed the dignitaries and workshop participants, while Dr MS Bhadwal, Dean, FVSc & AH, briefed the assembly on the details of the workshop. He explained the problems faced by farmers in their routine husbandry practices and asked the experts to update the field vets on the topics and areas involved. The workshop was jointly organized by the Division of Veterinary Parasitology and Veterinary Surgery and Radiology of FVSc & AH

The workshop aimed to update the knowledge of field veterinarians from the Sheep and Livestock Department and to adopt a collaborative approach in the field of veterinary research and field practices through interactions with field veterinarians, pharmaceutical companies. and scientists to develop common strategies and approaches. against animal diseases and their control. Dr. Gaurav Chaudhary, Technical Director of Vibrac Animal Health India Pvt. Ltd. presented a conference on the therapeutic uses of veterinary pharmaceuticals. Lectures on other different topics were given by experts, namely Prof. Rajesh Katoch, Prof. HRBhardwaj and Prof. Pankaj Goswmai.

Professor HR Bhardwaj (Course Director), Dr Ankur Sharma (Course Coordinator), Principal Scientist, KVK, Jammu, Faculty Members, Postgraduates and Committee Members attended the workshop . All participants received a certificate of participation. Dr Sanku Borkataki, Assistant Professor and Course Coordinator, Division of Veterinary Parasitology, thanked all the dignitaries, participants, committee members and specially sponsor of the Vibrac Animal Health India Pvt. Ltd ‘for the smooth running of the event.

GSK shares positive update from Omicron and new partnership with Oxford Thu, 02 Dec 2021 20:27:00 +0000

Léon Neal / Getty Images

As the Omicron variant continues to spread around the world, researchers are working to identify therapies that can prevent infections or reduce the risk of serious infections. This morning, GlaxoSmithKline early research shows that his monoclonal antibody is demonstrating its effectiveness against the most recent strain of COVID-19.

This morning, GSK and its partner Vir Biotechnology announced that preclinical tests show that sotrovimab, a monoclonal antibody cleared for use in mild to moderate COVID-19 by the US Food and Drug Administration (FDA) and the UK government, is effective against Omicron. The companies said the data shows that sotrovimab retains activity against key mutations in the new strain, including those found in the binding site of the monoclonal antibody treatment.

George Scangos, Ph.D., CEO of Vir Biotechnology, said that when developing sotrovimab, scientists at the company kept potential mutations in the virus in mind.

“By targeting a highly conserved region of the spike protein that is less likely to mutate, we hoped to fight both the current SARS-CoV-2 virus and future variants that we thought were inevitable,” Scangos said in a report. communicated. “This hypothesis has been confirmed time and time again, with its continued ability to maintain activity against all of the variants tested of concern and interest to date, including key mutations found in Omicron, as evidenced by preclinical data. We expect this positive trend to continue and we are working quickly to confirm its activity against Omicron’s full combination sequence. “

GSK’s head of R&D, Hal Barron, MD, said these early preclinical results support the two companies’ view that sotrovimab will be able to maintain its efficacy against emerging strains of SARS-CoV-2. Barron, also scientific director, said he was satisfied with the results of tests against Omicron, a treatment option that can help patients infected with the virus. He noted that companies are working to expand the availability of sotrovimab around the world.

To date, sotrovimab has demonstrated continued activity against all of the tested variants of concern and of interest as defined by the World Health Organization (WHO), GSK said this morning. GSK and Vir complete in vitro pseudo-virus tests which should confirm the neutralizing activity of sotrovimab against the combination of all Omicron mutations. The companies hope to provide an update on these tests by the end of 2021.

In November, the US government announced its intention to acquire $ 1 billion of sotrovimab. GSK is expected to respond to the supply of the monoclonal antibody by December 17.

In addition to its ongoing research against COVID-19, GSK also continues to target another deadly infectious disease, HIV. The company, soon to be split into two business units, hopes to develop a cure for HIV within the next eight years by 2030. Bloomberg reported, the company presented its target at an investor conference last month.

Kimberly Smith, MD, Head of Research and Development at HIV-focused ViiV Health, established through a partnership of GlaxoSmithKline, Pfizer, and Shinogi Limited, said the company aims to have a cure for the disease by 2030. In a previous interview with BioSpaceSmith highlighted advances in HIV treatment and pointed to some successes in two patients who became HIV-free through rigorous treatment options. She said it showed what is possible on the pitch.

Also this week, GSK and the University of Oxford entered into a five-year collaboration to accelerate research and development of new drugs. The collaboration forms the Oxford-GSK Institute for Molecular and Computational Medicine, which will build on advances in genetics, functional genomics and machine learning.

With an initial focus on neurological diseases such as Alzheimer’s and Parkinson’s disease, the institute will evaluate new approaches in genetics, proteomics, and digital pathology to understand detailed disease patterns that vary from year to year. patient to another. These diseases include multiple sclerosis, frontal temporal dementia, and amyotrophic lateral sclerosis.

The new institute was supported by an investment of almost $ 40 million from GSK. The progress made by the institute will benefit GSK’s own drug development programs that harness data about genetically informed drug targets generated by its collaborations with 23andMe and UK Biobank.

Source link

GBT supports the sickle cell disease program of the ASH Research Collaborative Data Hub Thu, 02 Dec 2021 13:00:00 +0000

WASHINGTON and SOUTH SAN FRANCISCO, California, December 2, 2021 / PRNewswire / – The ASH Research Collaborative (ASH RC), a nonprofit organization established in 2018 by the American Society of Hematology (ASH) and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) has announced today that GBT will provide a grant of $ 400,000 to ASH RC in support of the ASH RC Data Hub Sickle Cell Disease (SCD) program. With the Data Hub SCD program, ASH RC seeks to advance research and outcomes for people living with SCD by expanding its current data collection of real research-grade data to include more than half of people living with SCD in United States.

“We have a common mission with GBT to help transform the treatment of sickle cell anemia,” said Martin S. Tallman, MD, of Memorial Sloan Kettering Cancer Center, who is president of the ASH Research Collaborative and the American Society of Hematology. “By working closely with the SCD community, ASH RC is committed to effectively capturing real-world longitudinal data to better understand the natural history of sickle cell disease and to create a high-quality national data repository for accelerate research and improve clinical care. We aim to give the SCD community a meaningful voice in creating one of the world’s largest repositories of real, science-grade data in SCD. We appreciate the support from GBT to help us work to improve the care and outcomes for our patients with this rare disease. “

ASH RC fosters collaborative partnerships to advance advances in hematology and improve the lives of those affected by blood diseases. The foundation of ASH RC is its Data Hub, a multi-stakeholder real-world data program that facilitates the exchange of information on hematological conditions to support scientific research, discovery and quality improvement. Nearly 30 US clinical sites providing SCD care currently participate in the Data Hub and submit HIPAA compliant data representing 6,000 people living with SCD. The Data Hub is actively recruiting up to 110 additional clinical sites, and ASH RC believes it is well positioned to collect data on more than 50,000 people in the United States living with SCD.

GBT is the first biopharmaceutical company to provide financial support to ASH RC via a grant that will help onboard clinical sites and integrate their data into the Data Hub. These sites are organized into 19 consortia also registered in the ASH RC SCD clinical trials network. The goal of the SCD Clinical Trials Network is to accelerate research that advances the treatment and care of people affected by SCD.

“Comprehensive real-world data can empower people with sickle cell disease and their healthcare providers to make decisions about their care, while also guiding the development of new treatments and guidelines that we hope will transform CDS into a well-managed disease, ”said Kim smith whitley, MD, executive vice president and head of research and development at GBT. “GBT is proud to support ASH RC and its core mission of collecting real-world data to help meet the urgent needs of people with sickle cell disease. There has never been a more important time to advance research initiatives with the potential to improve care. and address long-standing health equity gaps for the SCD community. “

The Data Hub can collect a wide variety of data, including electronic medical record data, clinical and laboratory data, genomic or molecular correlates, patient-reported outcomes, and aggregated population data. This data is obtained from inpatient and outpatient clinical sites, industry or government datasets, registries, other US or international sources, and directly from patients. By using cutting-edge technology to automate clinical data entry and linkages to other data sources, the Data Hub focuses on reducing the burden of data entry. Patient information collected in the Data Hub complies with state and local privacy laws and regulations to protect patient privacy.

To learn more, please visit

About sickle cell anemia
Sickle cell disease affects more than 100,000 people in the United States,1 around 52,000 people in Europe,2 and millions of people around the world, especially among those whose ancestors originated from sub-Saharan Africa.3 It also affects people of Hispanic, South Asian, South European, and Middle Eastern ancestry.3 SCD is a rare inherited blood disorder that affects hemoglobin, a protein carried by red blood cells that provides oxygen to tissues and organs throughout the body.4 Due to a genetic mutation, people with sickle cell anemia form an abnormal hemoglobin called sickle hemoglobin. Through a process called hemoglobin polymerization, red blood cells become sickles – deoxygenated, crescent-shaped, and rigid.4-6 The sickling process causes hemolytic anemia (low hemoglobin level due to the destruction of red blood cells) and blockages in capillaries and small blood vessels, which impede the flow of blood and oxygen throughout the body. . Decreased oxygen supply to tissues and organs can lead to life-threatening complications, including stroke and irreversible organ damage.5-8

About the ASH Research Collaborative
The ASH Research Collaborative (ASH RC) is a non-profit organization created by the American Society of Hematology (ASH) to improve the lives of people affected by blood diseases by fostering collaborative partnerships to accelerate progress in hematology. The basis of ASH RC is its data center and clinical trials network. Through ASH RC’s state-of-the-art data sharing platforms and patient-centric approach to recruiting, designing and executing clinical trials for SCD, ASH RC enables companies to develop new treatments more quickly and efficiently to help people with blood problems and to maximize the value of these treatments after approval. The ASH RC aims to transform research and practice in malignant and non-malignant hematologic diseases around the world, for the benefit of patients and the hematologic community.

About Global Blood Therapeutics
Global Blood Therapeutics, Inc. (GBT) is a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments that give hope to underserved patient communities. Founded in 2011, GBT is achieving its goal of transforming the treatment and care of sickle cell anemia (SCD), a devastating, inherited blood disorder that lasts for life. The company introduced Oxbryta® (voxelotor), the first FDA-approved treatment that directly inhibits the polymerization of sickle hemoglobin, the root cause of sickle red blood cells in sickle cell disease. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase 3 development to treat pain attacks associated with disease, and GBT021601 (GBT601), the polymerization inhibitor of the company’s next-generation hemoglobin S. In addition, GBT’s drug discovery teams are working on new targets to develop the next wave of potential treatments for SCD. For more information, visit and follow the company on Twitter @GBT_news.

The references

  1. Centers for Disease Control and Prevention website. Research on sickle cell disease. Accessed December 1, 2021.
  2. European Medicines Agency. Accessed June 12, 2020.
  3. Centers for Disease Control and Prevention website. Sickle cell disease (SCD). Accessed June 3, 2019.
  4. National Heart, Lung and Blood Institute website. Sickle cell disease. Accessed August 5, 2019.
  5. Rees DC, et al. Lancet. 2010; 376 (9757): 2018-2031.
  6. Kato GJ, et al. Nat Rev Dis Primers. 2018; 4: 18010.
  7. Kato GJ, et al. J Clin Invest. 2017; 127 (3): 750-760.
  8. Caboot JB, et al. Paediatr Respir Rev. 2014; 15 (1): 17-23.

SOURCE American Society of Hematology

Source link

Study reveals new way to detect early risk of cardiovascular disease Thu, 02 Dec 2021 03:20:00 +0000

The risk of developing cardiovascular disease is strongly associated with “bad” LDL cholesterol. A large study by scientists at the Karolinska Institutet now shows that two proteins that transport cholesterol particles in the blood provide early and reliable information about the risks. The researchers are now advocating the introduction of new guidelines for detecting heart risk and say the findings could pave the way for early treatment, which could help reduce morbidity and mortality rates.

Cardiovascular disease is the most common cause of death worldwide and includes a wide range of conditions, such as stroke and myocardial infarction with atherosclerosis in different organs of the body. In many cases, the disease can be prevented and stopped with lifestyle changes and lipid-lowering treatments using statins and other methods.

The data typically used to assess elevated heart risk are benchmarks for “bad” LDL cholesterol. In some medical conditions, other types of fat particles are also measured along with apolipoproteins, which carry cholesterol in the blood. International guidelines on cardiovascular disease recommend using apolipoprotein apoB, which carries “bad” cholesterol, as an alternative risk marker for people with type 2 diabetes, overweight (high BMI) and lipid levels. very high blood.

However, recent research has indicated the importance of also taking into account the apolipoprotein apoA-1, which carries the “good” protective and anti-inflammatory HDL cholesterol. Calculating the apoB / apoA-1 ratio gives a risk quotient reflecting the balance between the “bad” particles of fat that accelerate atherosclerosis and the “good” protective particles of apoA-1 that stop the process.

In this study, researchers analyzed the link between cardiovascular disease and apoB / apoA-1 values ​​in more than 137,000 Swedish men and women aged 25 to 84. The individuals were followed for 30 years, during which 22,000 suffered some form of cardiovascular event. The analytical methods are simple, inexpensive, and safe, and do not require pre-testing on an empty stomach, as is the case with LDL and non-HDL testing. By basing their study on a large database (AMORIS), the researchers linked the lab tests to several registries of clinical diagnoses.

The results show that the higher the apoB / apoA-1 value, the higher the risk of myocardial infarction, stroke and the need for coronary surgery. The study also showed that the risk was magnified in the presence of low protective levels of apoA-1. “

Göran Walldius, Principal Author and Emeritus Professor, Institute of Environmental Medicine, Epidemiology Unit, Karolinska Institutet

People with the highest apoB / apoA-1 values ​​had a 70% higher risk of severe cardiovascular disease and an almost triple risk of non-fatal myocardial infarction compared to those with apoB / apoA values. -1 the weakest. Individuals with the highest risk quotient were also more affected by severe cardiovascular disease many years earlier than individuals with the lowest apoB / apoA-1 values.

The relationship has been observed in men and women and the elevated levels could be detected as early as 20 years before the onset of cardiovascular disease.

“Early preventive treatment and information about cardiovascular risk are, of course, important in enabling individuals to manage their risk situation,” says Walldius. “Early treatment can also reduce the financial burden on public health services. “

Overall, the results indicate that the apoB / apoA-1 ratio is a better marker for identifying more individuals at risk for future cardiovascular disease than the apoB method alone, according to the researchers.

“It should be possible to introduce cut-off values ​​for apoB, apoA-1 and the apoB / apoA-1 ratio in the new guidelines in addition to the current guidelines on the detection and treatment of dyslipidemia,” said declared Walldius.

The study was funded by the Gunnar and Ingmar Jungner Foundation for Laboratory Medicine.


Journal reference:

Walldius, G., et al. (2021) Long-term risk of a major cardiovascular event (MACE) by apoB, apoA-1 and the apoB / apoA-1 ratio – Swedish AMORIS cohort experience: A cohort study. PLoS medicine.

Source link

Antimicrobial resistance (AMR): a local problem and a global challenge Wed, 01 Dec 2021 13:01:55 +0000

To shorten it: In the future, available antimicrobial agents may not be effective in treating many potentially fatal bacterial infections in humans and pets.

The message is very simple, but if you read it several times and think about the possible consequences, the message makes you shiver.

Microbiologists have long warned of our challenges in the 21st century, as many scientists have predicted the possibility of an emerging viral pandemic1. In the real world, we have seen how unprepared we are for such eventualities. The same story is true for the problem of antimicrobial resistance (AMR) that Alexander Fleming in his 1945 interview with The New York Times warned that the misuse of antimicrobials leads to the selection of resistant bacteria 2.

It is likely that many scientific facts and predictions will not be applied as binding rules in policy making by countries and health authorities, as they might be so busy with the little issues of everyday life as with the search for proactive solutions.

AMR is a multi-faceted problem that requires a holistic view to be solved. We need to understand the perspective of health that sees human, animal and environmental health as an integrated system. Despite the urgent need to develop such systems, the one health approach still looks like an interesting idea rather than a practical, action-oriented approach in most situations or in most developing countries. 3, 4.

It is worth noting that AMR has been seen as a global challenge for the Sustainable Development Goals (SDGs) of many countries around the world, as discussed at the United Nations General Assembly in April 2021. 5 Volkan Bozkir the President of the UN General Assembly underlined the global importance of this unnoticed problem ” Antimicrobial resistance is the invisible pandemic that we ignore at our peril. Antimicrobial resistance measures must be at the heart of future COVID-19 pandemic preparedness and recovery plans. The One Health approach will help us to better recognize the interconnections between people, animals, plants and our common environment so that we can make our world a healthier place for all. “.5

In the 21st century, we, the global residents of planet Earth, are more connected than ever before, and a growing problem in a specific region could turn into an international crisis a few years later. On the other hand, there are several economic or geographic boundaries that prevent researchers from working together to solve large-scale global problems like AMR. How do you predict a better future when the issues are so intertwined and complex today?

Many scientists have already proven that they are ready to work together for a better future, despite the difficulties and limited resources. It seems that we need more international research groups in order to find more practical solutions to multifaceted problems like AMR.

The BMC series has turned out to be a great community that brings together different ideas of international importance freely accessible around the world. We are delighted to announce a new collection on AMR at BMC veterinary research, entitled Combat resistance to veterinary antimicrobials.

Submission to the collection is open until March 31, 2022, and we are happy to invite researchers to share their valuable insights of global significance to be considered for this collection.

  1. [ Accessed: 1 August 2021)
  2. Noah Rosenblatt-Farrell (2009) The Landscape of Antibiotic Resistance, Environ Health Perspect. 117(6): A244–A250  [doi: 1289/ehp.117-a244 ]
  3. [ Accessed: 1 August 2021]
  4. Mitchell MEV et al. (2020) The Challenges of Studying Antimicrobial Resistance in Vietnam – What Benefits Does a One Health Approach Offer to Animal and Human Health Sectors? BMC Public Health. 20: 213 (
  5. [ Accessed: 1 August 2021]
Sydney-based medical tech startup secures A $ 129 million led by Horizons Ventures – TechCrunch Wed, 01 Dec 2021 04:02:29 +0000

Founders of Founders of Dimitry Tran, Dr Colin Goldschmidt and Dr Aengus Tran Photo by Stefanie Zingsheim / The Photo Pitch, a Sydney-based company that creates medical devices with AI technology, today announced it has raised A $ 129 million (roughly US $ 92.3 million) in what it says is one of the biggest B Series towers ever made for an Australian healthcare tech company.

The funding was led by historic investor Horizons Ventures and included participation from new investors, Sonic Healthcare and I-MED Radiology Network. Existing backers Blackbird Ventures and Skip Capital also returned for the round, bringing the total raised by over the past two years to A $ 158 million. announced that it has also formed a joint venture with Sonic Healthcare, one of the world’s largest providers of medical diagnostics, to develop and commercialize new clinical AI solutions in pathology. The partnership will first focus on histopathology, or the diagnosis of tissue diseases.

This follows another joint venture formed with I-MED Radiology in early 2020, creating to develop AI-based radiological diagnostic aids. CEO Dr Aengus Tran told TechCrunch he became a doctor to help as many people as possible. “As I became more interested in artificial intelligence, I fell in love with the idea of ​​using AI to help more people than I could in my entire life. “ was started with his brother Dimitry to evolve the global capacity for quality healthcare by empowering clinicians with AI-powered tools. Dr Tran said has been able to launch its first regulatory-approved product in 18 months, an AI tool that detects clinical findings on chest x-rays.

The funding will also be used to hire more AI data scientists and engineers and form clinical partnerships around the world to expand into new areas of health. says its AI-based technology can help improve the diagnostic process in places where there is a shortage of healthcare.

“COVID has intensified the inequalities and struggles that the global health system already faces, especially in critical areas like radiology and pathology,” said Dr Tran. “Over the past decade and more, we have witnessed a critical shortage of radiologists in both developed and developing markets, and this has only worsened as COVID has resulted in further skills shortages and a backlog. elective procedures and requirements. “

He added that’s AI-based technology is designed to help evolve healthcare systems and is not meant to replace clinicians. “We empower them to make critical healthcare decisions quickly and at scale, with the help of artificial intelligence. “ currently has teams in Australia, UK and Vietnam, and plans to expand to other countries soon. Its products are ready to be marketed in Australia, the UK, Europe and some Asian countries, Dr Tran said. The company’s goal is to expand into other markets, with the goal of helping one million patients per day.

Source link

Anthony Broadwater breaks down in tears as Alice Sebold apologizes for false conviction in “Lucky” rape Tue, 30 Nov 2021 20:20:00 +0000

Eight days after Syracuse man Anthony Broadwater was cleared of Alice Sebold’s rape in 1981, the best-selling author apologized and called the Syracuse resident an “innocent man”.

Before issuing his apology to the public on Tuesday afternoon, Sebold’s representatives sent a copy to Broadwater so he could be the first to read it.

“It sincerely comes from her heart,” Broadwater told | The Post-Standard. “She knowingly admits what happened. I accept his apologies.

Broadwater then burst into tears.

RELATED: Behind the “Lucky” exemption: 2 lives filled with pain and 40 years of a man’s fight for justice

In her apology, later posted on the Medium website, Sebold wrote that she trusted the US justice system as an “18-year-old traumatized rape victim.” She launched her career in 1999 with the memoir “Lucky”, describing her rape in Syracuse’s Thornden Park and her journey through the criminal justice system that led to her conviction in 1982.

This sent Broadwater to 16 years in prison for a rape Sebold now believes he did not commit.

“It took me the last eight days to figure out how this could have happened,” Sebold wrote in a statement posted on Medium, an online publishing site. “I will continue to fight the role I unwittingly played in a system that sent an innocent person to jail.

Broadwater, Now 61, Exoneration Occurred a Week ago Monday in a Syracuse Courtroom and First Reported by | The Post-Standard. The only two pieces of evidence against Broadwater were the identification of Sebold at trial – after picking the wrong man from a previous police team – and the microscopic analysis of the hair, now considered unwanted science.

Broadwater told | The Post-Standard that he always tried to soak up Sebold’s lyrics. He was already in the office of his lawyers David Hammond and Melissa Swartz on Tuesday when representatives for Sebold reached out to show him what she had written.

Broadwater said it took a while for the apology to soak in. But after thinking about it and talking to his wife, his emotional weight overcame him.

“It was a great relief,” said Broadwater. “It must have taken a lot of courage to reconcile and apologize.”

Broadwater also issued a statement to | The Post-Standard through its lawyers.

“It is still painful for me because I have been wrongly convicted, but it will help me in my peace process with what has happened,” Broadwater said in the statement.

Alice Sebold, pictured in 2002, wrote the 1999 “Lucky” memoir about rape while a student at Syracuse University in 1981 and the fight for her assailant’s conviction. (Scribner; Associated Press)Scriber; Associated press

In his self-published statement, Sebold noted that the country is only now grappling with problems in the criminal justice system that may have contributed to Broadwater’s wrongful conviction.

“I’m grateful that Mr. Broadwater was finally vindicated, but the fact remains that 40 years ago he became another young black man brutalized by our flawed legal system. I will always be sorry for what was done to him, ”Sebold wrote.

“Today, American society is beginning to recognize and address systemic problems in our justice system that too often mean that justice for some comes at the expense of others. Sadly, it wasn’t a debate, or a conversation, or even a whisper when I reported my rape in 1981.

Writer Douglass Dowty can be contacted at or 315-470-6070.

Source link

AVMA’s National Awareness Campaign Promotes COVID-19 Vaccinations Mon, 29 Nov 2021 20:52:17 +0000 The organization urges members of the veterinary team, their clients and the public to get vaccinated.

The American Veterinary Medical Association (AVMA) has launched a nationwide education and awareness campaign urging veterinary teams, their clients, and the general public to get vaccinated against COVID-19.

According to a statement from the organization, the initiative was encouraged by the Centers for Disease Control and Prevention (CDC), which understands the vital role veterinarians play in society and public health. In addition, surveys have revealed that approximately 90% of AVMA members are currently vaccinated, demonstrating the value that veterinary professionals place in preventive care and their confidence in the safety and efficacy of the vaccine.

“We want our veterinary staff, our animal owners and our communities to be safe and healthy, and that is why we join with our colleagues in human medicine and science to actively promote the importance of COVID-19 vaccine, ”said José Arce, DVM, president of AVMA, in the statement.

“Veterinary medicine has a clear public health mission,” continued Arce. “In fact, when we take the oath, we are specifically committing to ‘promoting public health.’ Encouraging preventive health care, including immunization, is part of that commitment. Especially with the flu season underway. and the approach of winter, we strongly encourage vaccination to protect the general well-being of the public.

The campaign is expected to run until the end of December and will feature a wide range of print and digital materials available to AVMA members (e.g. a social media toolkit, brochures and posters for lobbies and veterinary offices) encouraging staff, animal owners and the public to receive the COVID-19 vaccine. These resources are available here:

“Vets are healthcare providers trusted not only by their clients but the general public, we understand the power of vaccines and have been recruited as COVID vaccination providers in some areas,” Arce said.

“We recognize that immunization is a choice and that not everyone can get it. But we are uniquely qualified to share the importance of disease prevention and control in animals and humans. Protecting public health is part of the veterinarian’s responsibility and appropriate preventive care, including vaccinations, goes a long way in protecting public health, ”he continued.


AVMA is launching a national awareness campaign to encourage vaccinations against COVID-19. Press release. American Association of Veterinary Medicine. November 22, 2021. Accessed November 29, 2021.

Agglutination of TDP-43 in ALS Related to Age-Related Loss in the Cellular Control System Mon, 29 Nov 2021 13:01:30 +0000

The loss of chemical changes in the regulatory sequence of TARDBP The gene, called DNA methylation, appears to help increase levels and clumping of the TDP-43 protein in the motor cortex of people with amyotrophic lateral sclerosis (ALS), according to a study.

As methylation of this gene – which stops the cellular machinery from reading this gene and making proteins – decreases with age, study results begin to explain why advanced age is a major risk factor. for ALS.

Age-related demethylation of the TDP-43 self-regulatory region in the human motor cortex»Was published in the journal Nature Communications Biology.

In over 95% of sporadic cases of ALS, the TDP-43 protein forms abnormal clumps in motor neurons, the nerve cells that control muscle movement. This aggregation leads to loss of motor neurons in an area of ​​the brain called the motor cortex and symptoms of disease.

Aging is a risk factor for motor neuron loss and the development of ALS, and researchers believe there may be a link between age and higher levels of TDP-43. However, the exact mechanism linking this protein to aging and the impact on motor neurons is still unknown.

recommended reading

The amount of TDP-43 is strictly controlled by how its messenger RNA – mRNA, the molecule that carries the instructions of the TARDBP gene to make the TDP-43 protein – is processed, via a mechanism called splicing.

Splicing essentially determines which parts of the gene are retained to be read by the protein manufacturing machinery. In the case of TARDBP, if too much TDP-43 protein is already in the nucleus, cells alter the splicing process to produce an mRNA molecule which is degraded and will not lead to protein production, thus helping to control TDP- levels. 43.

Since aging is associated with the loss of DNA methylation – the biological process by which methyl groups are added to DNA to suppress gene activity – researchers based at the University of Niigata in Japan wondered whether methylation of DNA from TARDBP genes change with age.

They also examined whether a change in methylation state could alter the splicing mechanism of TDP-43 mRNA to increase TDP-43 production in motor neurons, ultimately leading to aggregation and disease. .

“It’s a big mystery why TDP-43 selectively accumulates in the motor cortex as we age in ALS. TDP-43 accumulates as its amount increases, ”said Osamu Onodera, MD, PhD, director of the Brain Research Institute at the University of Niigata and lead author of the study, in a press release.

“However, TDP-43 itself is expressed in all cells, and the amount of TDP-43 in a cell is kept strictly constant through splicing,” Onodera added.

To find out, the researchers selectively demethylated the TARDBP gene to determine whether it affected TDP-43 expression and to study DNA methylation status in brain tissue collected post-mortem from seven patients with ALS and eight people without brain disease serving as a control group .

“Many neurological diseases, including ALS, have ‘aging’ as a risk factor. DNA methylation changes, which shape tissue specificity, are also affected by aging, which in turn affects splicing, ”said Onodera. “This is why we focused on methylation at the regulatory site of the TDP-43 gene.”

The team demonstrated that demethylation suppressed the correct splicing of TARDBP MRNA, with a 1.85-fold increase in unspliced ​​mRNA. In brain samples, the amount of DNA methylation in the cerebral cortex and cerebellum did not differ between ALS patients and controls.

In the motor cortex of the brain, however, control samples showed less methylation in TARDBP with advanced age. People in their 50s had about 80% DNA methylation, which fell to almost 50% in people in their 80s. Among older people, methylation was “extremely low,” the researchers noted.

No correlation between methylation and age was evident in patients with ALS. But their methylation levels were about 65% of those normally found at age 45, and similar to levels seen in people in their sixties and sixties.

Other experiments have shown that TARDBP expression tended to increase when DNA was demethylated in motor cortex samples, but this association was significant only in samples from the control group.

The researchers also measured the levels of TDP-43 protein in the tissues of the motor cortex. Although there was no association between DNA methylation levels and normally folded TDP-43 protein, less methylation was linked to more aggregated TDP-43.

Finally, they studied the relationship between TARDBP methylation in the motor cortex and clinical features of ALS patients. A significant correlation was found between less methylation in the TARDBP gene and age of onset of ALS, but not with the duration of the disease.

“Thus, the unique profile of TARDBP … DNA methylation in the motor cortex may contribute to susceptibility to TDP-43 pathology [disease] during brain aging in people with ALS, ”the researchers wrote.

“Regulation of methylation in the regulatory region of TDP-43 may provide a novel therapeutic approach for ALS,” said Onodera. “Tissue-specific and age-related methylation changes in disease-associated genes may also play a role in other neurodegenerative diseases.”

Source link

Future of American agriculture demands high-speed internet solutions Mon, 29 Nov 2021 03:27:45 +0000

ST. LOUIS – A new report, funded by the United Soybean Board and produced by the Benton Institute for Broadband & Society, has found that providing American farmers and ranchers with fast, affordable and reliable broadband access will increase sustainability. It will also enable more reliable and efficient food production for a growing population and strengthen rural American communities.

“Data is the most valuable tool in our farm’s toolbox. Without a reliable connection to the Internet, data collection and further use is severely limited, ”said Meagan Kaiser, USB treasurer, soil scientist, and Missouri farmer. “The data gives us the ability to identify the nutrient needs of plants and target those nutrients only where they are needed, leading to increased yields without expanding the acreage. It all starts with connectivity.

Interviews with farmers, rural internet service providers, equipment manufacturers, and agricultural leaders and experts revealed consensus around several key outcomes for rural broadband, such as the need for robust download speeds, accurate network deployment data and scalable technologies.

The report, The Future of American Farming: Broadband Solutions for the Farm Office, Field and Community, presents 15 concrete recommendations for delivering the high-speed internet that farmers and rural communities need.

Categorized by farm center, wireless needs in the field, and the reliability of broadband that can support the interdependent relationship between farmers and their rural communities, some of the concrete recommendations include:

• Establish performance standards that stand the test of time: To meet the growing demand of farmers for upstream and downstream speeds, networks must be able to provide 100/100 Mbps service.

• Adopt high-performance standards: Performance standards for download speeds and latency are expected to reflect farmers’ changing needs for precision farming.

• Encourage deep fiber buildup: Fiber construction in rural America, even if not directly on the farm, will be required to support capable wireless connections for higher bandwidth applications in the field.

• Filling the gaps in the mapping of agricultural land: Broadband maps should include mobile coverage on farmland. The underlying data that informs these maps must be publicly available.

• Support digital equity programs at state and local levels: Digital equity programs can work with communities to help people make full use of broadband connections.

“For many farmers, sustainability integrates the economic, environmental and social impacts of agriculture – a triple bottom line,” said Jordan Arnold, associate researcher at the Benton Institute for Broadband & Society and author of the report. “Now is the time to deploy the broadband networks and the adoption strategies they need. “

The recommendations are a direct response to problems revealed in a 2019 rural broadband study from USB. This initial study showed that 60% of American farmers and ranchers do not believe they have adequate internet connectivity to run their businesses and that plans to integrate data into everyday decisions are often thwarted by internet speeds. slow, high costs and unreliable service. The study also noted that many farmers have no other viable option to switch Internet service providers.

Even embarrassed by these issues, farmers know that broadband is a necessary tool to implement innovative agricultural practices and allow a more targeted and more efficient use of resources. Broadband access allows farmers to measure their inputs and outputs more efficiently, which creates smarter and more sustainable resource management.

“The connectivity of land, equipment and infrastructure allows for the proactive management of digital data at the farm and ranch level. Digital data management drives precision farming, and precision farming drives many fundamental aspects of measurable sustainability, ”said Mace Thornton, vice president of communications and marketing strategy for USB. “This is why this issue is so vital for soybeans.”

To read the full report, visit

Source link